Stock News & Analysis

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Coca-Cola boasts a 27% net margin but trades at a steep premium, while PepsiCo's diversified snacks portfolio commands a fraction of the valuation.

Investors simply need to stay the course.

Many of the catalysts that were supposed to send XRP much higher in the coming years are now in question.

Elon Musk says RAM supply is the core bottleneck in artificial intelligence (AI) infrastructure.

Costco is an all-weather stock.

Robinhood is demonstrating that Bitcoin is an asset that's worth holding for serious businesses.

These grocery stocks pay yields from 4.3% to 5.2%, funded by brands people buy every week.

These two crypto companies are betting big on the emerging AI agent economy.

SK Hynix trades at a fraction of AMD's valuation, but one company faces cyclical headwinds while the other wrestles with intense competition and supply chain risk.

100-bagger math run backward, Broadcom CEO calls AI trade a casino, and more...

MPLX has a growing dividend, but reaching a $6,000-a-year income from this midstream stock is an expensive proposition.

The company is burning through tons of cash, and that is likely to accelerate in the future.

A major source of Ethereum demand is about to disappear. That's a problem for investors.

Two important revenue boosters for the company are looking healthy these days.

The next market slump is inevitable. Adjusting your plans and perspective can help you get ready today.

Nvidia and Broadcom are two of the best-positioned stocks for the continued AI infrastructure boom.

Rocket Lab is launching rockets at a faster pace, with plans to put nearly 30% more satellites into orbit this year than last year.

Beneficiaries haven’t enjoyed Social Security raises of this magnitude since the 1990s.

One makes the chips, the other designs them. But their valuations and risk profiles diverge sharply.